Lexeo Therapeutics, Inc. (NASDAQ:LXEO – Free Report) – Equities researchers at Leerink Partnrs decreased their Q1 2024 earnings estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($1.10) per share for the quarter, down from their previous forecast of ($1.09). The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.04) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2024 earnings at ($1.09) EPS, Q3 2024 earnings at ($1.09) EPS, Q4 2024 earnings at ($1.08) EPS, FY2024 earnings at ($4.36) EPS, FY2025 earnings at ($4.39) EPS and FY2026 earnings at ($4.51) EPS.
Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last released its earnings results on Monday, March 11th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.15).
Lexeo Therapeutics Trading Up 2.8 %
Hedge Funds Weigh In On Lexeo Therapeutics
A number of hedge funds have recently made changes to their positions in LXEO. Eventide Asset Management LLC acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $40,298,000. Omega Fund Management LLC acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $28,955,000. Finally, Blackstone Inc. acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $9,342,000. Institutional investors and hedge funds own 60.67% of the company’s stock.
Lexeo Therapeutics Company Profile
Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.
Further Reading
- Five stocks we like better than Lexeo Therapeutics
- Stock Analyst Ratings and Canadian Analyst Ratings
- MarketBeat Week in Review – 4/22 – 4/26
- Pros And Cons Of Monthly Dividend Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- Using the MarketBeat Dividend Tax Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.